Literature DB >> 28776170

Viridans group streptococci bloodstream infections in neutropenic adult patients with hematologic malignancy: Single center experience.

J Radocha1, P Paterová2, A Zavřelová3, B Víšek3, F Gabalec3, H Žemličková2, P Žák3.   

Abstract

Viridans group streptococci bloodstream infections (VGS BSI) remain a significant cause of mortality and morbidity in patients with severe neutropenia. The goal of our study was to evaluate clinical course and microbiological susceptibility of VGS BSI at our center. Retrospective analysis of all microbiologically documented bloodstream infections caused by VGS during the 9-year time period (from January 2006 until December 2014) was carried out. Only patients with severe neutropenia (< 500/μL) were included in the study. Clinical outcome and microbiological susceptibility pattern of isolates were recorded. Fifty-one individual patients with episode of VGS BSI were identified. The most frequent agent was Streptococcus mitis (23/51 cases, 45.1%). 88.2% (45/51) of patients were on recommended ciprofloxacin prophylaxis. 20/51 (39.2%) of patients suffered from mucositis at the time of diagnosis (10 patients had oral mucositis, 2 patients had bowel mucositis, and 8 patients both). Twenty-six patients (51.0%) had clinically relevant lung damage caused by VGS BSI (i.e., acute lung injury or acute respiratory distress syndrome). Twenty-four (47.0%) patients presented with bilateral lung infiltrated upon chest imaging, and two (4.0%) patients had unilateral lung infiltrates. Three patients (5.9%) died due to VGS BSI until day 28 of observation. No difference in signs of shock syndrome was observed in the patients during transplantation procedures compared to patients without transplantation as well as in a group received previous high-dose chemotherapy with cytosinarabinoside or in patients with mucositis. Only 3/51 of isolates (5.9%) were resistant to penicillin. All isolates were susceptible to empirical treatment. While the penicillin resistance of VGS remains low in middle Europe, initial antibiotic therapy of febrile neutropenia are still effective in most cases. The mortality and complication rates of VGS BSI were comparable to other studies, and no specific risk factor of shock presence could be identified.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28776170     DOI: 10.1007/s12223-017-0542-7

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  24 in total

1.  Viridans streptococci bacteremia in children with malignancy: relevance of species identification and penicillin susceptibility.

Authors:  Entesar Husain; Sue Whitehead; Annette Castell; Eva E Thomas; David P Speert
Journal:  Pediatr Infect Dis J       Date:  2005-06       Impact factor: 2.129

2.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

Review 3.  Viridans-group streptococcal infections in immunocompromised hosts.

Authors:  J L Shenep
Journal:  Int J Antimicrob Agents       Date:  2000-03       Impact factor: 5.283

4.  Infections caused by viridans streptococci in patients with neutropenia.

Authors:  Allan R Tunkel; Kent A Sepkowitz
Journal:  Clin Infect Dis       Date:  2002-05-06       Impact factor: 9.079

5.  Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors.

Authors:  L S Elting; G P Bodey; B H Keefe
Journal:  Clin Infect Dis       Date:  1992-06       Impact factor: 9.079

6.  Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer.

Authors:  J Carratalá; F Alcaide; A Fernández-Sevilla; X Corbella; J Lińares; F Gudiol
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

7.  Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients.

Authors:  Adam Gassas; Ronald Grant; Susan Richardson; L Lee Dupuis; John Doyle; Upton Allen; Oussama Abla; Lillian Sung
Journal:  J Clin Oncol       Date:  2004-04-01       Impact factor: 44.544

8.  Reduced susceptibility to penicillin of viridans group streptococci in the oral cavity of patients with haematological disease.

Authors:  K Westling; I Julander; P Ljungman; A Heimdahl; A Thalme; C E Nord
Journal:  Clin Microbiol Infect       Date:  2004-10       Impact factor: 8.067

Review 9.  Infections with viridans group streptococci in children with cancer.

Authors:  Anne F Reilly; Beverly J Lange
Journal:  Pediatr Blood Cancer       Date:  2007-11       Impact factor: 3.167

10.  Clinical characteristics and antimicrobial susceptibilities of viridans streptococcal bacteremia during febrile neutropenia in patients with hematologic malignancies: a comparison between adults and children.

Authors:  Seung Beom Han; E Young Bae; Jae Wook Lee; Dong-Gun Lee; Nack-Gyun Chung; Dae-Chul Jeong; Bin Cho; Jin Han Kang; Hack-Ki Kim
Journal:  BMC Infect Dis       Date:  2013-06-17       Impact factor: 3.090

View more
  3 in total

1.  [Analysis of pathogens and clinical characteristics of bloodstream infection in neutropenic children with hematological malignancies from 2014 to 2018].

Authors:  G Q Zhu; C H Xu; Q S Lin; X X Wang; L L Wang; N N Zhao; S Z Feng; Y M Chen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-08-14

2.  [A single-center study on the distribution and antibiotic resistance of pathogens causing bloodstream infection in adult patients with hematological disease during the period 2014-2018].

Authors:  C H Xu; G Q Zhu; Q S Lin; L L Wang; X X Wang; J Y Gong; N N Zhao; D L Yang; S Z Feng
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-08-14

3.  An intubated 7-month-old infant with a retropharyngeal abscess and multidrug-resistant Streptococcus mitis.

Authors:  Yoshihisa Watanabe; Yoshiro Nagao; Hisashi Endo; Ichiro Yamane; Masaaki Hirata; Kuniya Hatakeyama
Journal:  Clin Case Rep       Date:  2019-11-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.